Welcome to the Pharmacometabolomics Research Network (PMRN) Website (a network founded by NIGMS funding).
We are a research center associated with the department of Psychiatry and Behavioral Sciences in the Duke University School of Medicine.
The PMRN has the goal of integrating the rapidly evolving science of metabolomics with molecular pharmacology and pharmacogenomics to move toward the goal of “individualized” drug therapy and subclassification of disease based on treatment outcomes. We have formed collaborative projects joining centers of excellence in metabolomics and metabolomic bioinformatics with centers of excellence in pharmacogenomics and molecular pharmacology. The goal is to achieve an environment in which clinicians, analytical chemists, biochemists, biologists, pharmacologists, geneticists, psychologists, statisticians, mathematicians, and engineers can create a new field called Pharmacometabolomics.
-- Rima Kaddurah-Daouk, PI
Find out about our:
Metabolomics - The Global Science of Biochemistry
The goal of the Pharmacometabolomics Research Network is to integrate the rapidly evolving science of metabolomics with molecular pharmacology and pharmacogenomics to move toward the creation of a new discipline, Pharmacometabolomics, which aims to move to individualized drug therapy, where drugs are selected based on the metabolic status and the genetic make up of each individual.
Here we will showcase practical applications of pharmacometabolomics with two completed studies:
- Study 1: Pharmacometabolomics of statins in the treatment of hyperlipidemia.
- Study 2: Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions.